Search hospitals
>
Quebec
>
MONTREAL
CHUM-Centre Hospitalier de l'Universite de Montreal
Claim this profile
MONTREAL, Quebec H2X 3E4
Global Leader in Breast Cancer
Global Leader in Lung Cancer
Conducts research for Prostate Cancer
Conducts research for Cancer
Conducts research for Pancreatic Cancer
466 reported clinical trials
99 medical researchers
Summary
CHUM-Centre Hospitalier de l'Universite de Montreal is a medical facility located in MONTREAL, Quebec. This center is recognized for care of Breast Cancer, Lung Cancer, Prostate Cancer, Cancer, Pancreatic Cancer and other specialties. CHUM-Centre Hospitalier de l'Universite de Montreal is involved with conducting 466 clinical trials across 625 conditions. There are 99 research doctors associated with this hospital, such as Daniel Von Renteln, MD, Diane Provencher, MD, FRCSC, Jean Raymond, MD, and Moishe Liberman, MD.
Area of expertise
Breast Cancer
CHUM-Centre Hospitalier de l'Universite de Montreal has run 66 trials for Breast Cancer. Some of their research focus areas include:
Lung Cancer
CHUM-Centre Hospitalier de l'Universite de Montreal has run 49 trials for Lung Cancer. Some of their research focus areas include:
Top PIs
Daniel Von Renteln, MD
Centre Hospitalier de l'Université de Montréal (CHUM)
2 years of reported clinical research
Diane Provencher, MD, FRCSC
Centre Hospitalier de l'Université de Montréal
6 years of reported clinical research
Jean Raymond, MD
Centre Hospitalier de l'Université de Montréal
15 years of reported clinical research
Moishe Liberman, MD
CHUM
3 years of reported clinical research
Clinical Trials running at CHUM-Centre Hospitalier de l'Universite de Montreal
Prostate Cancer
Breast Cancer
Cancer
Lung Cancer
Head and Neck Cancers
Colorectal Cancer
Cardiovascular Disease
Oropharyngeal Cancer
Brain Tumor
Glaucoma
Darolutamide + SBRT
for Prostate Cancer
This trial tests a combination of precise radiation therapy and a hormone-blocking drug in prostate cancer patients with limited spread. It aims to control the disease and delay more toxic treatments. The approach targets small areas of cancer spread and blocks the cancer's growth signals. The hormone-blocking drug is a novel treatment approved for specific prostate cancer cases.
Recruiting
2 awards
Phase 2
3 criteria
PSMA-PET Imaging
for Prostate Cancer
Prostate cancer (PCa) is the most common non-skin malignancy and the third leading cause of cancer death in North American men. The accurately mapped metastatic state is a necessary prerequisite to guiding treatment in practice and in clinical trials. Imaging biomarkers (BMs) can provide information on disease volume and distribution, prognosis, changes in biologic behavior, therapy-induced changes (both responders and non-responders), durations of response, emergence of treatment resistance, and the host reaction to the therapies. Of particular relevance to metastatic prostate cancer is the emergence of a promising imaging technique involving new prostate specific membrane antigen (PSMA) positron emission tomography (PET) tracers. This approach has demonstrated higher sensitivity in detecting metastases, prior to and during therapy, than current imaging standard of care (CT and bone scan), and is not widely clinically available outside of the research realm in North America. Positron emission tomography / computer tomography (PET/CT) is a nuclear medicine diagnostic imaging procedure based on the measurement of positron emission from radiolabeled tracer molecules in vivo. PSMA is a homodimeric type II membrane metalloenzyme that functions as a glutamate carboxypeptidase/folate hydrolase and is overexpressed in PCa. PSMA is expressed in the vast majority of PCa tissue specimens and its degree of expression correlates with a number of important metrics of PCa tumor aggressiveness including Gleason score, propensity to metastasize and the development of castration resistance. \[18F\]DCFPyL is a promising high-sensitivity second generation PSMA-targeted urea-based PET probe. Studies employing second-generation PSMA PET/CT imaging in men with biochemical progression after definitive therapy suggest detection of metastases in over 60% of men imaged. Deep learning is defined as a variant of artificial neural networks, using multiple layers of 'neurons'. Deep learning has been investigated in medical imaging in numerous applications across organ systems. In oncology, basic artificial neural networks to support decision-making have previously been developed retrospectively in breast cancer and prostate cancer, but have not been validated or integrated prospectively. Novel data-driven methods are needed to predict outcomes as early as possible in order to guide the duration and the aggressiveness of a particular therapy. They are also needed for optimal patient selection based on the patient's response to a given therapy. Here the investigators hypothesize that the combination of a highly performing prostate cancer imaging technique combined with machine learning has high potential. The main objective of this study is to acquire PSMA-PET data in patients with prostate cancer who receive treatment and follow-up in order to enable the discovery of predictive imaging biomarkers through deep learning techniques.
Recruiting
2 awards
Phase 3
1 criteria
Opevesostat + Hormone Therapy
for Prostate Cancer
This trial is testing a new drug called opevesostat for advanced prostate cancer patients who don't respond to usual care. The drug aims to stop the cancer from growing and spreading, potentially helping patients live longer.
Recruiting
2 awards
Phase 3
10 criteria
Similar Hospitals nearby
Frequently asked questions
What kind of research happens at CHUM-Centre Hospitalier de l'Universite de Montreal?
CHUM-Centre Hospitalier de l'Universite de Montreal is a medical facility located in MONTREAL, Quebec. This center is recognized for care of Breast Cancer, Lung Cancer, Prostate Cancer, Cancer, Pancreatic Cancer and other specialties. CHUM-Centre Hospitalier de l'Universite de Montreal is involved with conducting 466 clinical trials across 625 conditions. There are 99 research doctors associated with this hospital, such as Daniel Von Renteln, MD, Diane Provencher, MD, FRCSC, Jean Raymond, MD, and Moishe Liberman, MD.
Where is CHUM-Centre Hospitalier de l'Universite de Montreal located?
**Centre Hospitalier de l'Université de Montréal (CHUM)** - **Location:** 1051 Sanguinet Street, Montreal, Quebec, Canada. Features underground city access to Champ-de-Mars metro station. - **Type:** Public not-for-profit corporation. - **Funding:** Supported by Quebec taxpayers via the Ministry of Health and Social Services.
Who should I call to ask about financial aid or insurance network?
For financial assistance and insurance-related inquiries at CHUM-Centre Hospitalier de l'Universite de Montreal: - **Financial Support - CHUM**: For information about financial support, please consult the CHUM website. - **Université de Montréal Contact**: Reach out at 514 343-6111 or mail to PO Box 6128, Centre-ville Station, Montréal, Quebec, H3C 3J7 for guidance or direction to the appropriate department. - **Student Financial Assistance - Québec**: Contact the Student Financial Assistance office at the Ministry of Higher Education in Québec at their client services from Monday to Friday, 8:30 a.m. to 12:00 p.m. and 1:00 p.m. to 4:30 p.m., with extended hours on Wednesdays.
What insurance does CHUM-Centre Hospitalier de l'Universite de Montreal accept?
The Centre hospitalier de l'Université de Montréal (CHUM) is a public not-for-profit hospital funded mainly by Quebec taxpayers. CHUM accepts the Régie de l'assurance maladie du Québec (RAMQ) for Quebec residents, covering hospital care, physician services, and certain diagnostics. For those without RAMQ coverage, including international patients, CHUM provides private healthcare options and participates in international medical programs.
What awards or recognition has CHUM-Centre Hospitalier de l'Universite de Montreal received?
The CHUM Research Centre (CRCHUM) at the Centre Hospitalier de l'Universite de Montreal is renowned for its significant contributions to health research, as evidenced by its annual Research Awards of Excellence. It has also earned an "exceptional" rating in the 2020-2026 strategic plan by the Fonds de recherche du Québec — Santé, highlighting its outstanding performance in research activities.
Unbiased Results
We believe in providing patients with all the options.
Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.
Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.
Unbiased Results
We believe in providing patients with all the options.
Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.
Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.